Hawaii ERS Has a Strong First Quarter

The fund’s unique risk strategy is paying off right now.

The first numbers are in for the Hawaii Employees’ Retirement System (ERS)’s new fiscal year, which began on July 1. The portfolio gained 2.1% in the first fiscal quarter, beating its target benchmark of 1.5%, according to an article in the Honolulu Star-Advertiser.

Thom Williams, who is the executive director of the $21 billion fund, said these numbers bode well for the overall long-run sustainability of the pension.

“Although the recent results represent only a single quarter, it infers we are on track to achieve our long-term investment target of 7% annually,” he said in a written statement. “Attaining, or exceeding, our investment objective serves to reduce the long-term cost of the plan to the state, counties, and taxpayers. Improving the plan’s sustainability and affordability is our goal.”

Never miss a story — sign up for CIO newsletters to stay up-to-date on the latest institutional investment industry news.

Hawaii ERS attained a record-breaking 26.2% return in the previous fiscal year from July 2020 to June 2021. However, in some ways, this quarter’s 2.1% is even more impressive than that record-breaking number, since it comes after a relatively slow quarter in the equities market. The S&P grew only 0.2% over the period between July 1 and Sept. 30, and the Dow Jones decreased by 0.2%.

Hawaii ERS’ staff attributed its success to the fund’s unique risk strategy and its investments in its “private growth” asset class (mostly private equity) which had 12.5% returns this quarter. Hawaii ERS’ strategy is designed so that it generally outperforms its peers during bear markets and underperforms during bull markets.

Hawaii ERS Chief Investment Officer Elizabeth Burton used this quarter’s returns to make a case for active management.

“We do believe this quarter—and the prior quarters—demonstrate the value an in-house investment staff adds over passive beta strategies (such as buying an index fund),” she said in a written statement.

Williams also said staffing is critical to Hawaii ERS’ success. “The fund’s outperformance relative to our benchmarks and peers is due almost entirely to manager selection and portfolio construction,” he said. 

Related Stories:

2019 Power 100 Elizabeth Burton: After Her First Year at Hawaii ERS

Why Bother With Active Management When Mechanistic Passive Does Best Historically?

Exclusive: ‘Bull Market Is Going to Go for Another Few Years.’—Florida SBA Senior Investment Officer Talks Strategy.

Tags: , , , , , , ,

Positive Pandemic News Lifts Stocks, as Moderna Touts 3-Dose Regimen

The biotech firm says its booster shot gives good protection against Omicron.

In this grim Yuletide season, the mounting COVID-19 case loads and the onset of the Omicron variant have sent the market reeling over the past three trading days. Early trading points to a possible rebound today.

If so, some of the credit goes to news from Moderna that its booster, atop two previous full-dose shots, gives significant protection against the new variant. These glad tidings join a similar upbeat announcement from Pfizer and BioNTech two weeks ago that a third shot of their vaccine also restored protection to a point close to the initial two-dose combo against the original virus. 

Also helping the market is a report from South Africa, where the variant was first identified, that daily infections dropped to the lowest level in two weeks. This gives hope that the new strain’s effect will be short and shallow, and not harm economic activity. 

Never miss a story — sign up for CIO newsletters to stay up-to-date on the latest institutional investment industry news.

Of course, it’s unclear how long the boosters’ effectiveness will last. Moderna also indicated it is getting ready to test an updated vaccine for use against Omicron and other variants. While the S&P 500 was up just under 1% in morning trading, Moderna stock continued to fall, as did that of Pfizer.

And even a three-shot regimen has proved to be, at least in a minority of instances, no shield against the coronavirus. Latest example: CNBC host Jim Cramer said Monday that he has tested positive, with a mild case, even though he had a triple dose of the Moderna vaccine.

«